Interference of the expression of IL-17 at the posttranscriptional level could enhance the apoptosis of LC cell lines via activation of the FAS/FASL pathway, suggesting that IL-17 can be targeted for therapeutic intervention against LC. The gene discussed is FASLG; the disease is laryngotracheoesophageal cleft.